CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Transgene Biotek Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Transgene Biotek Ltd
C-44, Madhuranagar, S R Nagar
Phone: +91 8458279744p:+91 8458279744 HYDERABAD, 502315  India Ticker: 526139526139
Business Summary
Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in the research and development of vaccines, oncology and new drug delivery technologies. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The Company offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20243/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Managing Director K. KoteswaraRao 3/4/2020 1/17/2020
Director Shyam S.Das 46 12/31/2014 12/31/2014
Additional Director VikramPolavarapu 3/4/2020 11/12/2019
3 additional Officers and Directors records available in full report.

Business Names
Business Name
526139
Transgene Biotek Ltd

General Information
Outstanding Shares: 75,770,001 (As of 3/31/2024)
Shareholders: 12,191
Stock Exchange: BOM
Fax Number: +91 8458279755


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024